Company profile
Xeno Transplants Corporation
OTC: XENO · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 43
v0.1 · 5/100 weight · pillars only
↑ listing tenure, return on assets · ↓ Piotroski F, market scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$128.2k
Employees
—
as of 2026-08-30
Market cap
$4.0k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02006
Net income-$128.2k-$128.2k2006
Operating income$128.2k$128.2k2006
Total assets$641.4k$641.4k2006
Liabilities$255.4k$255.4k2006
Equity$386.0k$386.0k2006
Revenue trend
FY2004 – FY2006 · USD
FY04
FY05
FY06
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Xeno Transplants Corporation’s revenue?
Xeno Transplants Corporation booked $0 in FY2006 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Life Stem Genetics Inc.——Innovation1 Biotech Inc.——ForU Holdings, Inc.——Claritas Pharmaceuticals, Inc.——Rapid Therapeutic Science Laboratories, Inc.——Sienna Biopharmaceuticals, Inc.——Neighbors
Norfolk →Key facts
CEOElliot Lebowitz
SectorHealthcare
IndustryBiotechnology
HeadquartersBrookline, MA
ExchangeOTC: XENO
Employees—
IPO date2006-08-01
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.